CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

Table 2

Overall survival-3 years. This table shows an increase in overall survival after 3 years with tumors positive for CDK9 as compared to those negative for CDK9.

		Overall survival (years)
Covariate	Level	Hazard Ratio	HR P-value	Type3 P-value
CDK9 (Less than 3 years)	Positive	0.99 (0.30-3.23)	0.982	0.982
	Negative	-
CDK9 (Greater than 3 years)	Positive	0.26 (0.07-0.98)	0.046	0.046
	Negative	-

Number of observations in the original data set = 84.
Number of observations used = 67.